International Assets Investment Management LLC Acquires 128,715 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

International Assets Investment Management LLC boosted its holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 934.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,491 shares of the biotechnology company’s stock after purchasing an additional 128,715 shares during the period. International Assets Investment Management LLC’s holdings in Coherus BioSciences were worth $474,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. SteelPeak Wealth LLC grew its position in Coherus BioSciences by 27.8% in the fourth quarter. SteelPeak Wealth LLC now owns 69,000 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 15,000 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Coherus BioSciences by 430.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 10,454 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Coherus BioSciences in the fourth quarter valued at $244,000. Public Employees Retirement System of Ohio acquired a new stake in Coherus BioSciences in the third quarter valued at $96,000. Finally, Vanguard Group Inc. lifted its stake in Coherus BioSciences by 10.5% in the third quarter. Vanguard Group Inc. now owns 9,782,127 shares of the biotechnology company’s stock valued at $36,585,000 after acquiring an additional 932,476 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Stock Performance

NASDAQ CHRS opened at $1.93 on Friday. The firm has a 50-day moving average of $2.36 and a 200-day moving average of $2.50. The stock has a market cap of $219.06 million, a PE ratio of -0.75 and a beta of 0.54. Coherus BioSciences, Inc. has a 52-week low of $1.43 and a 52-week high of $8.22.

Coherus BioSciences (NASDAQ:CHRS) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.39). The firm had revenue of $91.52 million for the quarter, compared to the consensus estimate of $105.30 million. As a group, analysts predict that Coherus BioSciences, Inc. will post -0.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. HC Wainwright cut their price target on shares of Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, March 20th. Robert W. Baird cut their price target on shares of Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, January 23rd. Finally, Truist Financial cut their price target on shares of Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Coherus BioSciences currently has a consensus rating of “Moderate Buy” and an average price target of $9.29.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.